Feed NRXP
NR

NRx Pharmaceuticals, Inc.

NRXP · NASDAQ

$3.32 +0.45% (+$0.01)
1M -4.64%
Market Cap $56.9M
P/E Ratio -
Div. Yield -
ROE -

Bulios Fair Price

$3.36

1.2% upside

Current Price

$3.32

Undervalued Fair Value Overvalued

According to Bulios Fair Price, NRXP is currently trading close to its fair value. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Moderate
4/9
Valuation
0 /100
Expensive
P/S 16.76x
P/E N/A
EV/EBITDA N/A
Growth
-
N/A
EPS growth N/A
Rev. growth N/A
FCF growth N/A
Profitability
12 /100
Weak
Gross margin 32.68%
Net margin 691.81%
Op. margin 588.24%
Quality
2 /100
Poor
ROIC 1,855.48%
ROA 68.74%
Asset turnover 0.10x
Debt
12 /100
High
Current ratio 0.86x
Int. coverage -19.52x
Debt/Equity N/A
Stability
1 /100
Unstable
Beta 2.19x
EPS volatility 349.46%
Profitable years 0

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about NRXP
Online

About the company

NRx Pharmaceuticals, Inc. (NRXP) is a pharmaceutical company focused on research and development of new drugs for the treatment of serious diseases. The company specializes in therapeutic approaches for diseases that currently lack effective treatments or have inadequate treatment options. NRx Pharmaceuticals emphasizes innovation and utilizes modern technologies and scientific knowledge to discover new treatment possibilities. Their drugs are aimed at potential treatments for diseases in areas such as neurology, oncology, infectious diseases, and more. The company is actively developing drugs and conducting clinical trials to confirm the effectiveness and safety of their products. NRx Pharmaceuticals aims to bring new drugs to the market that can make a significant improvement for patients with serious diseases. NRx Pharmaceuticals, Inc. (NRXP) shares may be an attractive investment opportunity for investors interested in the pharmaceutical sector and seeking an investment in a company focused on innovative therapeutic approaches for serious diseases.

Sector

Healthcare

Industry

Biotechnology

CEO

Jonathan C. Javitt

Employees

29

Headquarters

Wilmington

Upcoming events

13 NOV

Earnings

Upcoming earnings report

52d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.